CLChristopher Liang

Christopher Liang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher Liang has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    [18F]Flortaucipir binding and affinity to tau protein measured in postmortem human brains of Alzheimers disease and Down syndrome by autoradiography: Comparison with [ 18 F]MK-6240

    by Agnes P Biju, Josie M Herrera, Chloe C McNamara, Emma Lynn M Hipolito, Christopher Liang, Jogeshwar Mukherjee

    Flortaucipir and MK-6240 are two tau imaging agents currently in use for measuring neurofibrillary tangle (NFT) progression in Alzheimers disease (AD). The aims of this study were to use postmortem AD and Down syndrome (DS) brain sections to study three issues: (1) Measure binding affinity of flortaucipir and MK-6240 in AD brain sections by using [125I]IPPI; (2) Evaluate the binding characteristics of [18F]flortaucipir in AD, DS and cognitively normal (CN) brains sections and compare them with [18F]MK-6240, and (3) Assess the binding of [18F]flortaucipir in CN and Parkinsons disease (PD) brain sections to identify any off-target binding. The half-maximal inhibition (IC50) of [125I]IPPI bound to anterior cingulate (AC) in AD brain sections for flortaucipir was 2.91 nM and MK-6240 was 5.99 nM. Using frontal cortex (FCX) and temporal cortex (TCX) of AD, DS and CN brain sections, [18F]flortaucipir displayed high levels of binding in the gray matter (GM) of AD and DS. The average ratio of DSAD GM to CN GM was 15.7 in FCX, while DSAD GM to CN GM was 15.2 for the TCX. In the case of AD, average ratio of AD GM to CN GM was 12.4 in FCX, while AD GM to CN GM was 9.5 for the TCX. Binding of [18F]flortaucipir in brain section of AC from CN and PD cases did not exhibit any off-target binding to monoamine oxidase-A (MAO-A). In summary, both flortaucipir and MK-6240 exhibit similar high affinity to tau and [18F]flortaucipir exhibits higher binding compared to [18F]MK-6240 in DSAD.

  • Open Access

    Imaging [18F]FDG PET/CT pilot study of nicotinic acetylcholinergic receptor α2 knock-out mice and α2 hypersensitive mice compared to control mice: Male-female differences and nicotine effects

    by Christopher Liang, Titus E. Tucker, Ashlee D. L. Coronel, Ellen H. N. Nguyen, Janet L. Nguyen, Irakli Intskirveli, Ronit Lazar, Raju Metherate, Jogeshwar Mukherjee

    Nicotinic acetylcholinergic receptors (nAChRs), comprising of α and β subunits are present in the brain and whole body. The less abundant α2-subunit is a fast-acting receptor subtype and plays an important role in cognition and learning. To understand cellular functional consequences, this study evaluated glucose metabolism using [ 18 F]FDG PET/CT in α2 knockout (α2KO) and α2 hypersensitive (α2HS) mice. Control (CN; 4M, 3F), α2 knockout (α2KO; 4M, 4F) and α2 hypersensitive (α2HS; 4M,4F), 12–16 month old mice were used. Mice were fasted and injected with [ 18 F]FDG (3–5 MBq) while awake. After 40 minutes they underwent whole body PET/CT. On a separate day, nicotine challenge [ 18 F]FDG studies were done. Reconstructed images were analyzed to obtain standard uptake values (SUV) of [ 18 F]FDG in brain and interscapular brown adipose tissue (IBAT). Statistical analysis was performed comparing the three groups of mice. The α2HS male mice exhibited the largest brain increase in [ 18 F]FDG compared to α2KO male mice. The rank order of brain [ 18 F]FDG uptake in the three groups: α2HS♂ > CN♂ > α2KO♂ > CN♀= = α2KO♀ ≥ α2HS♀. Nicotine treatment reduced brain [ 18 F]FDG uptake in all mice. Females had lower [ 18 F]FDG uptake compared to males and were less sensitive to α2 nAChR. In the case of IBAT, α2KO mice had significantly higher baseline [ 18 F]FDG uptake compared to the other two groups: α2KO♂ > α2KO♀ > α2HS♀ > α2HS♂ > CN♀ > CN♂. Nicotine decreased IBAT in α2KO mice rather than increase as observed in CN and α2HS mice.This preliminary study shows that α2 nAChRs play a significant role in brain activation as exhibited by the increase in [ 18 F]FDG in α2HS mice. In the absence of regulatory control by the α2 nAChR, the α2KO mice IBAT exhibited higher [ 18 F]FDG uptake compared to controls and α2HS mice. Female mice were less affected by nicotine compared to the male mice.

  • Open Access

    Down syndrome postmortem brains exhibit reduction in [ 18 F]nifene binding to α4β2* nicotinic acetylcholinergic receptors

    by Fariha Karim, Nancy Paola Chavez-Jacobo, Christopher Liang, Elizabeth Head, Jogeshwar Mukherjee

    Alzheimer’s disease (AD) pathology including amyloid beta (Aβ) plaques and tau tangles accumulate with age in Down Syndrome (DS). Cholinergic abnormalities such as expression of nicotinic acetylcholine receptors (nAChRs) adversely contribute to cognitive decline and neurodegeneration in AD with similar features possible in DSAD. As a radiotracer for α4β2* nAChRs, [ 18 F]nifene was quantitatively evaluated in the frontal cortex (FCX) and temporal cortex (TCX) of DSAD, AD, and cognitively normal (CN) brain tissue using autoradiography. Anti-tau and anti-Aβ immunostaining in adjacent sections confirmed the presence of tau tangles and Aβ plaques. [ 18 F]Nifene binding in brain sections demonstrated significantly more binding in gray matter (GM) than white matter (WM), with FCX exhibiting more binding than TCX (OptiQuant). Nicotine substantially displaced [ 18 F]nifene binding in adjacent sections, resulting in average GM/nicotine ratios (DSAD=9.74, AD=10.5, CN=17; suggesting a 38% decrease in AD and a 43% decrease in DSAD) and WM/nicotine ratios (DSAD=2.73, AD=3.31, CN=5.62; suggesting a 41% decrease in AD and a 51% decrease in DSAD). [ 18 F]Nifene was correlated with [ 125 I]IBETA (Aβ), showing a strong positive relationship between α4β2* nAChRs and Aβ in DSAD. [ 18 F]Nifene GM/nicotine and WM/nicotine ratios were positively correlated with age in TCX and FCX. The findings of this study suggest that [ 18 F]nifene has potential use in diagnostic investigations of the cholinergic system in DSAD using positron emission tomography. The study also points to a possible need for earlier therapeutic interventions to address the α4β2* nAChRs deficit in DSAD. SIGNIFICANCE STATEMENT: People with Down syndrome are vulnerable to Alzheimer disease along with decreased cholinergic function, which may be linked to cognitive decline. The accumulation of amyloid plaques and tau associated with Alzheimer’s disease initiation and progression may be linked to cholinergic dysfunction in Down syndrome. Here we report decreases in α4β2 nicotinic acetylcholine receptors in Down syndrome frontal and temporal cortex. This receptor subtype is important for several brain functions, and loss of this receptor therefore contributes to some of the cognitive deficits seen in Down syndrome with increasing age.

  • Open Access

    Increased Binding of [ 18 F]Nifene, a PET Imaging Probe for α4β2* Nicotinic Acetylcholinergic Receptors in Hippocampus-Subiculum of Postmortem Human Parkinson’s Disease Brain

    by Jogeshwar Mukherjee, Fariha Karim, Allyson Ngo, Christopher Liang, Geidy E. Serrano, Thomas G. Beach

    Non-motor symptoms in Parkinson’s disease (PD) may be influenced by the α4β2* subtype of nicotinic acetylcholine receptors (nAChR) present in the hippocampus and subiculum. To continue efforts in PET diagnostics for PD, autoradiographic [ 18 F]nifene binding to α4β2* nAChR was quantitively assessed in the hippocampus-subiculum (HP-SUB) of PD (n = 27; 14 males, 13 females) and cognitively normal (CN) (n = 32; 16 males, 16 females) cases. Anti-ubiquitin for Lewy body and anti-α-synuclein immunostaining on adjacent slices were analyzed in QuPath and [ 18 F]nifene binding was quantified in OptiQuant. Subiculum had greater [ 18 F]nifene binding (51% to 85%) compared to HP in all subjects. Significantly higher [ 18 F]nifene binding (>250%) was seen in PD SUB and PD HP compared to CN in both males and females. The grey matter (GM) to white matter (WM) ratio in PD=3.53 while CN=1.33, a >150% increase in PD. Binding of [ 18 F]nifene to GM and WM individually was >250% greater in PD compared to CN. Male CN exhibited an increase while and male PD exhibited a significant decrease in [ 18 F]nifene binding with aging, while females did not exhibit significant differences. In summary, α4β2* nAChR measured by [ 18 F]nifene is significantly upregulated in the PD HP and SUB. This increased [ 18 F]nifene binding may be of diagnostic value using PET imaging.

  • Open Access

    Imaging [18F]FDG PET/CT Study of Nicotinic Acetylcholinergic Receptor α2 Knock-Out Mice and α2 Hypersensitive Mice Compared to Control Mice: Male-Female Differences and Nicotine Effects

    by Christopher Liang, Titus E. Tucker, Ashlee D.L. Coronel, Ellen H.N. Nguyen, Janet L. Nguyen, Irakli L. Intskirveli, Ronit L. Lazar, Raju L. Metherate, Jogeshwar Mukherjee

    Objective: Nicotinic acetylcholinergic receptors (nAChRs), comprising of a and b subunits are present in the brain and whole body. The less abundant α2-subunit is a fast-acting receptor subtype and plays an important role in cognition and learning. To understand cellular functional consequences, this study evaluated glucose metabolism using [18F]FDG PET/CT in α2 knockout (α2KO) and α2 hypersensitive (α2HS) mice. Methods: Control (CN; 4M, 4F), α2 knockout (α2KO; 4M, 4F) and α2 hypersensitive (α2HS; 4M,4F), 12-16 month old mice were used. Mice were fasted and injected with [18F]FDG (3-5 MBq) while awake. After 40 minutes they underwent whole body PET/CT. On a separate day, nicotine challenge [18F]FDG studies were done. Reconstructed images were analyzed to obtain standard uptake values (SUV) of [18F]FDG in brain and interscapular brown adipose tissue (IBAT). Statistical analysis was performed. Results: The α2HS male mice exhibited the largest brain increase in [18F]FDG compared to α2KO male mice. The rank order of brain [18F]FDG uptake in the 3 groups: α2HS♂> CN♂> α2KO♂> CN♀= α2KO♀≥α2HS♀. Nicotine treatment reduced brain [18F]FDG uptake in all mice. Females had lower [18F]FDG uptake compared to males and were less sensitive to α2 nAChR. In the case of IBAT, α2KO mice had significantly higher baseline [18F]FDG uptake compared to the other two groups: α2KO♂> α2KO♀> α2HS♀> α2HS♂> CN♀> CN♂. Nicotine decreased IBAT in α2KO mice rather than increase as observed in CN and α2HS mice. Conclusions: α2 nAChRs plays a significant role in brain activation as exhibited by the increase in [18F]FDG in α2HS mice. In the absence of regulatory control by the α2 nAChR, the α2KO mice IBAT exhibited higher [18F]FDG IBAT compared to controls and α2HS mice. Female mice were less affected by nicotine compared to the male mice. Overall, α2 nAChRs played a significant role in glucose metabolism in the brain and IBAT.

  • Open Access

    Evaluation of [18F]MK-6240 binding to tau protein in postmortem human brains of Down syndrome and Alzheimer’s disease and assessment of off-target (non-tau) binding

    by Fariha Karim, Agnes P. Biju, Christopher Liang, Camryn J. Santos, Maharishi Rajarethenam, Jogeshwar Mukherjee

    Alzheimer's disease (AD) and Down Syndrome (DS) are characterized by the aggregation of tau tangles. As a novel tau PET tracer in AD, [ 18 F]MK-6240 has the potential in Down syndrome-associated Alzheimer’s disease (DSAD) to elucidate pathophysiology and advance diagnostic strategies. Autoradiography of frontal cortex and temporal cortex postmortem brain slices of DSAD (n = 5), AD (n = 5), and cognitively normal (CN) (n = 5) cases indicated similarly high [ 18 F]MK-6240 binding in DSAD and AD cases. [ 18 F]MK-6240 binding in CN was substantially less than DSAD and AD. Anti-tau immunostains confirmed total tau presence that aligned with the localization of [ 18 F]MK-6240 binding. DSAD and AD cases exhibited higher gray matter (GM)/white matter ratios of 2.8 and 2.5 respectively. For drug effects on [ 18 F]MK-6240 binding, self-displacement by MK-6240 (10 µM) reduced binding by 88% among DSAD cases and 85% among AD cases while IPPI (10 µM) displaced [ 18 F]MK-6240 by 81% and 74% in DSAD and AD cases respectively. KuFal194 (10 µM), a specific phosphokinase inhibitor, minimally displaced [ 18 F]MK-6240 binding. Harmine competed with [ 18 F]MK-6240 with an IC 50 value of 290 nM and 92 nM for DSAD and AD cases, respectively. High meninges off-target (non-tau) binding of [ 18 F]MK-6240 was observed in a CN case, comparable to the GM in DSAD and AD. MK-6240 (10 µM) blocked 44% and T807 (10 µM) blocked 30% of meninges binding. Incubation of meninges in the presence of 0.2% polyethyleneimine reduced 70% of [ 18 F]MK-6240 binding. The tau radioligand, [ 125 I]IPPI, an analog of [ 18 F]MK-6240, exhibited minimal binding to CN meninges compared to the DSAD and AD cases. Our findings suggest [ 18 F]MK-6240 to be selective tau imaging agent in DSAD and AD, harmine to uniquely compete with [ 18 F]MK-6240 binding in DSAD and provide preliminary insights to the off-target nonspecific binding of [ 18 F]MK-6240 in postmortem meninges.


  • Open Access

    Measurement of tau protein and Aβ amyloid plaques in postmortem human brains of Down syndrome and Alzheimer’s disease by using [ 125 I]IPPI and [ 125 I]IBETA autoradiography

    by Agnes P. Biju, Fariha Karim, Deanna M. Schafer, Stephanie A. Sison, Christopher Liang, Elizabeth Head, Jogeshwar Mukherjee

    The accumulation of tau tangles and Aβ plaques are prominent neuropathologies that characterize Alzheimer’s disease (AD) and Down Syndrome (DS). Continuous developments of PET tracers as biomarkers can be supported by autoradiography to validate effectiveness and accuracy of binding properties that elucidate the pathophysiology of DSAD and AD. This in vitro comparative study evaluates [ 125 I]IPPI binding to tau and [ 125 I]IBETA binding to Aβ plaques in the frontal cortex (FCX) and temporal cortex (TCX) of postmortem human brain slices of AD (n=5), DSAD (n=5), and cognitively normal (CN) (n=5) cases. With anti-tau and anti-Aβ immunostains confirming the presence of tau and Aβ plaques, [ 125 I]IPPI and [ 125 I]IBETA binding in autoradiographic images were significantly higher in DSAD and AD gray matter (GM) compared to CN. When comparing DSAD with AD, FCX and TCX GM binding was similar throughout DSAD and AD except in FCX GM where there was 48% more [ 125 I]IPPI binding in DSAD than AD. In vitro drug inhibition studies revealed that [ 125 I]IPPI binding was significantly inhibited with increasing harmine concentrations (IC 50 =115±40 nM) in DSAD FCX and TCX but KuFal194 minimally inhibited [ 125 I]IPPI binding in the same cases. The GM/white matter ratios for DSAD ([ 125 I]IPPI=4.1, [ 125 I]IBETA=2.9) and AD ([ 125 I]IPPI=4.2, [ 125 I]IBETA=2.6) were significantly greater than CN ([ 125 I]IPPI=1.3, [ 125 I]IBETA=1.2). A positive correlation between [ 125 I]IPPI and [ 125 I]IBETA binding suggests a synergistic relationship between tau and Aβ plaque in DSAD and AD pathology. This study demonstrates that [ 125 I]IPPI and [ 125 I]IBETA may serve as novel radiotracers in both DSAD and AD to continue diagnostic investigations in vivo.

  • Open Access

    Evaluation of [18F]MK-6240 binding to tau protein in postmortem human brains of Down syndrome and Alzheimer’s disease and assessment of off-target (non-tau) binding

    by Fariha Karim, Agnes P. Biju, Christopher Liang, Camryn J. Santos, Maharishi Rajarethenam, Jogeshwar Mukherjee

    Alzheimer's disease (AD) and Down Syndrome (DS) are characterized by the aggregation of tau tangles. As a novel tau PET tracer in AD, [ 18 F]MK-6240 has the potential in DSAD to elucidate pathophysiology and advance diagnostic strategies. Autoradiography of frontal cortex (FCX) and temporal cortex (TCX) postmortem brain slices of DSAD (n = 5), AD (n = 5), and cognitively normal (CN) (n = 5) cases indicated similarly high [ 18 F]MK-6240 binding in DSAD and AD cases. Anti-tau immunostains confirmed total tau presence so there was alignment in anti-tau abundance with quantification of [ 18 F]MK-6240 binding. DSAD and AD cases exhibited higher gray matter (GM)/white matter (WM) ratios of 2.8 and 2.5 respectively. For drug effects on [ 18 F]MK-6240 binding, self-displacement of [ 18 F]MK-6240 was by 88% among DSAD cases and 85% among AD cases while IPPI displaced [ 18 F]MK-6240 by 81% and 74% in DSAD and AD cases respectively. KuFal194, a specific phosphokinase inhibitor, minimally displaced [ 18 F]MK-6240 binding. Harmine competed with [ 18 F]MK-6240 with an IC 50 value of 290 ± 218 nM and 92 ± 15 nM for DSAD and AD cases, respectively, suggesting unique tau binding. High meninges off-target (non-tau) binding of [ 18 F]MK-6240 was observed in a CN case, comparable to the GM in DSAD and AD. MK-6240 (10 µM) blocked 44% and T807 (10 µM) blocked 30% of meninges binding. Incubation of meninges in the presence of 0.2% polyethylenimine reduced 70% of [ 18 F]MK-6240 binding. The tau imaging agent, [ 125 I]IPPI, an analog of [ 18 F]MK-6240, exhibited minimal binding to CN meninges. Our findings suggest [ 18 F]MK-6240 to be selective tau imaging agent in DSAD and AD, harmine to be a weak tau drug, and off-target nonspecific meninges binding maybe due to the primary aromatic amine group in [ 18 F]MK-6240.

  • Open Access

    [18F]Mefway: Imaging Serotonin 5HT1A Receptors in Human Postmortem Alzheimer’s and Parkinson’s Disease Anterior Cingulate. Potential Applications to Human Positron Emission Tomography Studies

    by Noresa L. Gonzaga, Fariha Karim, Christopher Liang, Jogeshwar Mukherjee

    Serotonin 5HT1A receptors may be affected in neurodegeneration, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Using the selective 5HT1A receptor positron emission tomography (PET) imaging agent, [18F]mefway, autoradiographic studies from postmortem human brains of AD, PD, and cognitively normal (CN) subjects were carried out. Levels of [18F]mefway binding were compared with monoamine oxidase A (MAO-A) measured using [18F]FAZIN3 binding and dopamine D2/D3 receptors measured using [18F]fallypride binding in the same subjects. Autoradiograms of brain sections of the anterior cingulate and corpus callosum from CN, PD, and AD subjects (n = 6 in each group) were analyzed. Significant increased binding of [18F]mefway was found in the AD (+30%) and PD (+11%) brains compared to CN brains. This increase positively correlated to increased [18F]FAZIN3 binding, suggesting greater 5HT1A receptor availability when MAO-A levels are higher. Differences in [18F]fallypride binding in the three groups were not significant. Our results support the finding that the availability of 5HT1A receptors in AD and PD is elevated in the anterior cingulate cortex and is negatively correlated with MAO-A. This upregulation may potentially be a response to lower serotonin levels due to the increased levels of MAO-A activity in this brain region or other neuroinflammatory changes. Thus, 5HT1A receptors may be a potential target for diagnostic and therapeutic approaches for AD and PD.


  • Open Access

    Reduction in [18F]Nifene Binding, a PET imaging Probe for α4β2* Nicotinic acetylcholinergic receptors in Hippocampus-Subiculum of postmortem human Alzheimer’s disease brain

    by Fariha Karim, Allyson Ngo, Tram B. Danh, Brooke A. Delaney, Christopher Liang, Geidy E. Serrano, Thomas G. Beach, Jogeshwar Mukherjee